

Edgar Filing: RIBAPHARM INC - Form SC 13G

RIBAPHARM INC  
Form SC 13G  
February 12, 2003

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

SCHEDULE 13G  
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN THE STATEMENTS FILED PURSUANT  
TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED  
PURSUANT TO RULE 13d-2(b)

Ribapharm Inc.

(Name of Issuer)

Common Stock, par value \$.01 per share

(Title of Class of Securities)

762537108

(CUSIP Number)

December 31, 2002

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this  
Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's  
initial filing on this form with respect to the subject class of securities,  
and for any subsequent amendment containing information which would alter the  
disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be  
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange  
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of  
the Act but shall be subject to all other provisions of the Act (however, see  
the Notes).

CUSIP No. 762537108

13G

Page 2 of 5 Pages

1 NAME OF REPORTING PERSON  
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON  
ICN Pharmaceuticals, Inc.

Edgar Filing: RIBAPHARM INC - Form SC 13G

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
[ ] (a)  
[ ] (b)

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION  
Delaware

NUMBER OF  
SHARES  
BENEFICIALLY  
OWNED BY  
EACH  
REPORTING  
PERSON  
WITH

5 SOLE VOTING POWER  
120,100,000

6 SHARED VOTING POWER  
-0-

7 SOLE DISPOSITIVE POWER  
120,100,000

8 SHARED DISPOSITIVE POWER  
-0-

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
120,100,000

10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN  
SHARES [ ]

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
80.1%

12 TYPE OF REPORTING PERSON  
CO

Item 1(a). Name of Issuer.

Ribapharm Inc.

Item 1(b). Address of Issuer's Principal Executive Offices.

3300 Hyland Avenue  
Costa Mesa, CA 92626

Item 2(a). Name of Person Filing.

ICN Pharmaceuticals, Inc.

Edgar Filing: RIBAPHARM INC - Form SC 13G

Item 2(b). Address of Principal Business Office or, if None, Residence.

3300 Hyland Avenue  
Costa Mesa, CA 92626

Item 2(c). Citizenship.

Delaware

Item 2(d). Title of Class of Securities.

Common Stock, par value \$.01 per share

Item 2(e). CUSIP Number.

762537108

Item 3. If this Statement is Filed Pursuant to Rules 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

Not applicable as this Schedule is filed pursuant to Rule 13d-1(d).

Item 4. Ownership.

(a) Amount beneficially owned:  
120,100,000 shares

(b) Percent of class:  
80.1%

(c) Number of shares as to which such person has:

(i) Sole power to vote or direct the vote:  
120,100,000 shares

(ii) Shared power to vote or direct the vote:  
-0-

(iii) Sole power to dispose or to direct the disposition:  
120,100,000 shares

(iv) Shared power to dispose or to direct the disposition:  
-0-

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Edgar Filing: RIBAPHARM INC - Form SC 13G

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 11, 2003

ICN PHARMACEUTICALS, INC.

By: /s/ Gregory Keever

-----  
Name: Gregory Keever  
Title: Executive Vice President,  
General Counsel and  
Corporate Secretary